by GlyTherix | Mar 3, 2021
GlyTherix Ltd is proud to be a recipient of the first round of the Pipeline Accelerator 2020-21 scheme from Therapeutic Innovation Australia (TIA). Round 1 saw the award of $685,000 to 21 projects. Our project “Optimisation and characterisation of Miltuximab®-DFO...
by GlyTherix | Sep 10, 2020
PRESS RELEASE September 10, 2020 Adelaide, Australia and Sydney, Australia. CAR-T biotherapeutics company Carina Biotech and immuno-oncology company GlyTherix are pleased to announce a co-development agreement that could result in a promising new CAR-T therapy that is...
by GlyTherix | May 19, 2020
Tuesday 19th May 2020: Sydney GlyTherix Ltd (GlyTherix) is pleased to report publication of four new peer reviewed papers covering both basic science as well as pre-clinical studies around our proprietary novel target, Glypican-1 and our lead antibody to this target,...
by GlyTherix | Sep 19, 2019
GlyTherix is among 25 biotech companies presenting at the AusBiotech Invest & Partnering Session on Thursday 31 October at Melbourne Convention & Exhibition Centre. Brad Walsh will provide an update on Miltuximab, the company’s novel treatment for solid...
